Protection From Acute Kidney Injury (AKI) With Basis™ Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

March 14, 2024

Study Completion Date

March 14, 2024

Conditions
AKI
Interventions
DRUG

Nicotinamide Riboside + Pterostilbene

It will be administered a total of 1000 mg/day of NR and 200 mg/day of Ptero in a regimen of 2 capsules of Basis™ (each capsule 250 mg of NR and 50 mg of Ptero) 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.

DRUG

Placebo

The correspondent placebo will be administered in a regimen of 2 capsules 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Elysium Health

INDUSTRY

lead

Mayo Clinic

OTHER

NCT04342975 - Protection From Acute Kidney Injury (AKI) With Basis™ Treatment | Biotech Hunter | Biotech Hunter